For example, the prevalence of myositis-specific autoantibodies (MSA: anti-Jo-1, anti-Mi-2, anti-SRP, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ) and myositis-associated autoantibodies (MAA: anti-SSA/Ro-52, anti-Ku, anti-PM/Scl75, anti-PM/Scl100) in polymyositis/dermatomyositis does not exceed a total of 34.4% (MSA) and 41.4% (MAA), respectively [45]. Here, TRIM21 is linked to myositis disease.